Prevalence of JAK2 V617F, CALR, and MPL W515L Gene Mutations in Patients with Essential Thrombocythemia in Kurdistan Region of Iraq |
Saeed, Bestoon Muhammad
(Department of Hematology, Hiwa Hemato-Oncology Center)
Getta, Hisham Arif (Department of Pathology, College of Medicine, University of Sulaymaniyah) Khoshnaw, Najmaddin (Department of Hematology, Hiwa Hemato-Oncology Center) Abdulqader, Goran (Department of Pathology, College of Medicine, University of Sulaymaniyah) Abdulqader, Aveen M. Raouf (Department of Pathology, College of Medicine, University of Sulaymaniyah) Mohammed, Ali Ibrahim (Department of Pathology, College of Medicine, University of Sulaymaniyah) |
1 | Wang J, Zhang B, Chen B, Zhou R, Zhang Q, Li J, et al. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. Hematology. 2017;22:145-148. https://doi.org/10.1080/10245332.2016.1252003 DOI |
2 | Kim BH, Cho YU, Bae MH, Jang S, Seo EJ, Chi HS, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. J Korean Med Sci. 2015;30:882-888. https://doi.org/10.3346/jkms.2015.30.7.882 DOI |
3 | Kim SY, Im K, Park SN, Kwon J, Kim J, Lee DS. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015;143:635-644. https://doi.org/10.1309/AJCPUAAC16LIWZMM DOI |
4 | Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol. 2015;144:165-171. https://doi.org/10.1309/AJCPALP51XDIXDDV DOI |
5 | Lang T, Nie Y, Wang Z, Huang Q, An L, Wang Y, et al. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics. J Int Med Res. 2018;46:4650-4659. https://doi.org/10.1177/0300060518787719 DOI |
6 | Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-2390. https://doi.org/10.1056/NEJMoa1311347 DOI |
7 | Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, et al. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. PLoS ONE. 2013;8:e52518. https://doi.org/10.1371/journal.pone.0052518 DOI |
8 | Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000 Research. 2016;5:1-13. https://doi.org/10.12688/f1000research.8081.1 DOI |
9 | Ji L, Qian M, Wu N, Wu J. Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia. Exp Ther Med. 2017;13:947-951. https://doi.org/10.3892/etm.2017.4077 DOI |
10 | Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:1-10. DOI |
11 | Ojeda MJ, Bragos IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF. CALR, JAK2 and MPL mutation status in argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018;23:208-211. https://doi.org/10.1080/10245332.2017.1385891 DOI |
12 | Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107:673-680. https://doi.org/10.1007/s12185-018-2421-7 DOI |
13 | Syeed N. JAK2 and Beyond: JAK2V617 mutational study of myeloproliferative disorders and haematological malignancies. Asian Pac J Cancer Prev. 2019;20:3611-3615. https://doi.org/10.31557/APJCP.2019.20.12.3611 DOI |
14 | Jaradat SA, Khasawneh R, Kamal N, Matalka I, Al-Bishtawi M, Al-Sweedan S, et al. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:160-166. https://doi.org/10.1016/j.hemonc.2015.07.004 DOI |
15 | Nancy LM, Samantha GB, Javier GE, Perla CP, Valeria GO, Virginia RN, et al. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:16-21. https://doi.org/10.1016/j.hemonc.2014.12.002 DOI |
16 | Vu HA, Thao TT, Dong CV, Vuong NL, Chuong HQ, Van PNT, et al. Clinical and hematological relevance of JAK2V617F, CALR, and MPL mutations in Vietnamese patients with essential thrombocythemia. Asian Pac J Cancer Prev. 2019;20:2775-2780. https://doi.org/10.31557/APJCP.2019.20.9.2775 DOI |
17 | Li MY, Chao HY, Sun AN, Qiu HY, Jin ZM, Tang XW, et al. Clinical significance of JAK2, CALR, and MPL gene mutations in 1648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center. chinese Journal of Hematology. 2017;38:295-300. https://doi.org/10.3760/cma.j.issn.0253-2727.2017.04.007 DOI |
18 | Geduk A, Atesoglu EB, Tarkun P, Mehtap O, Hacihanefioglu A, Demirsoy ET, et al. The role of beta-catenin in Bcr/Abl negative myeloproliferative neoplasms: an immunohistochemical study. Clin Lymphoma Myeloma Leuk. 2015;15:785-789. https://doi.org/10.1016/j.clml.2015.08.084 DOI |
19 | Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10:2-8. https://doi.org/10.1186/s13045-017-0425-z DOI |
20 | Gardner JA, Peterson JD, Turner SA, Soares BL, Lancor CR, Dos Santos LL, et al. Detection of CALR mutation in clonal and non clonal hematologic diseases using fragment analysis and next-generation sequencing. Am J Clin Pathol. 2016;146:448-455. https://doi.org/10.1093/ajcp/aqw129 DOI |
21 | Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C. MPL W515L mutation in Chinese patients with myeloproliferative diseases. Leuk Lymphoma. 2008;49:955-958. https://doi.org/10.1080/10428190802035966 DOI |
22 | Chen X, Qi X, Tan Y, Xu Z, Xu A, Zhang L, et al. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Blood Cells Mol Dis. 2011;47:67-71. https://doi.org/10.1016/j.bcmd.2011.04.004 DOI |
23 | Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, et al. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. Intern Med. 2011;50:2557-2561. https://doi.org/10.2169/internalmedicine.50.5429 DOI |
24 | Smaili W, Doubaj Y, Laarabi FZ, Lyahyai J, Kerbout M, Mikdame M, et al. CALR gene mutational profile in myeloproliferative neoplasms with nonmutated JAK2 in Moroccan patients: a case series and germline in-frame deletion. Curr Res Transl Med. 2017;65:15-29. https://doi.org/10.1016/j.retram.2016.08.002 DOI |
25 | Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica. 2012;97:1582-1585. |
26 | Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847-1849. https://doi.org/10.1038/sj.leu.2403902 DOI |
27 | Lee KK, Cho H, Chi H, Kim DY, Chae SL, Huh HJ. A Case of postessential thrombocythemia myelofibrosis with severe osteosclerosis. Korean J Lab Med. 2010;30:122-125. https://doi.org/10.3343/kjlm.2010.30.2.122 DOI |
28 | Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187-4190. https://doi.org/10.1182/blood-2005-03-1287 DOI |
29 | Ma W, Kantarjian H, Zhang X, Yeh C, Zhang Z, Verstovsek S, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11:49-53. https://doi.org/10.2353/jmoldx.2009.080114 DOI |
30 | Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. https://doi.org/10.1016/S0140-6736(05)71142-9 DOI |
![]() |